A European Medicines Agency (EMA) committee has recommended that Ultomiris (ravulizumab) be approved to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now be reviewed by the European…
Ultomiris
Ultomiris (ravulizumab) — Alexion Pharmaceuticals’ approved therapy for certain complement-associated disorders — prevents relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy also helped preserve walking skills, with treated patients showing a markedly lower risk of experiencing clinically…
Recent Posts
- How to power through each day, even if you’re living with NMOSD
- Estrogen may drive brain inflammation in NMOSD: Mouse study
- I may have the dragon fruit of diseases, but let’s not compare apples to oranges
- 17-year-old advocate shares her NMOSD story to raise awareness
- Brain, nerve damage link to relapse, disability in AQP4-related NMOSD